Hung et al. reported that the therapeutic effect of the combination of anti-PD-1 and anti-TIGIT antibody was correlated with both increased effector T cell function and downregulation of suppressive Tregs and tumor-infiltrating DCs using the intracranial injection of murine glioblastoma GL261 [44]. Here, PDCD1 is linked to neoplasm.